Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer

BACKGROUND: Apatinib has shown outstanding value in the treatment of advanced gastric cancer (AGC). However, no biomarkers are available to select AGC patients who will benefit from apatinib. The aim of the present study was to investigate the association between p53 and Ki67 expression of and the o...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Zhiyuan, Qin, Rong, Zhang, Ziyi, Zhang, Ting, Zhang, Zhao, Qiao, Chunyue, Xi, Yan, Tian, Guangyu, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466417/
https://www.ncbi.nlm.nih.gov/pubmed/37655112
http://dx.doi.org/10.3389/fonc.2023.1203980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466417/
https://www.ncbi.nlm.nih.gov/pubmed/37655112
http://dx.doi.org/10.3389/fonc.2023.1203980

Ejemplares similares